Lyell Immunopharma, Inc.: 5%+ holders

As of November 10, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Lyell Immunopharma, Inc. The largest reported stake is ARCH Venture Fund IX, L.P.'s, at 13.9%. 12 filings are on record since August 1, 2025 (Schedule 13G/A, May 15, 2026).

Gates Frontier, LLC also filed stake reports on 1 other company ↓

Sell to companies like Lyell Immunopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Foresite Capital Fund IV, L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-06-18 · Reporting person: Innovative Cellular Therapeutics Holdings Limited · Sole voting: 3,000,000 · Shared voting: 0 · Sole dispositive: 3,000,000 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-06-18
• Filed 2026-05-15 · Holder: ARCH Venture Fund IX, L.P. · Percent: 13.9% · SCHEDULE 13G/A
• Filed 2026-05-11 · Holder: MWG Caph Ltd · Percent: 4.3% · SCHEDULE 13G/A
• Filed 2026-05-08 · Holder: Explore Investments LLC · Percent: 6.6% · SCHEDULE 13G/A

Lyell Immunopharma, Inc. has 12 Schedule 13D or 13G filings on record since 2025-08-01. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Lyell Immunopharma, Inc. and the warning signs.

See Lyell Immunopharma, Inc.'s free Snapshot Watch Lyell Immunopharma, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Lyell Immunopharma, Inc. and the records around it.

Lyell Immunopharma, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Gates Frontier, LLC also filed stake reports on 1 other company: Evolv Technologies Holdings, Inc. (Sep 2025)
• Newton (PTC) Limited also filed stake reports on 1 other company: Figure Technology Solutions, Inc. (Nov 2025)
• ARCH Venture Fund IX, L.P. also filed stake reports on 2 other companies: Vir Biotechnology, Inc. (Nov 2026), Sana Biotechnology, Inc. (Aug 2026)

Want the whole picture on Lyell Immunopharma, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Lyell Immunopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Lyell Immunopharma, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   12 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Lyell Immunopharma, Inc. by CUSIP 55083R203 and gives its principal executive office as 201 Haskins Way, South San Francisco, CA 94080 (SCHEDULE 13G/A, 2026-08-14).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Lyell Immunopharma, Inc.

Who owns Lyell Immunopharma, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Lyell Immunopharma, Inc.: ARCH Venture Fund IX, L.P. (13.9%, Schedule 13G/A, filed 2026-05-15), Innovative Cellular Therapeutics Holdings Limited (12.3%, Schedule 13G/A, filed 2026-06-18), Euler Fund, L.P. (6.71%, Schedule 13G, filed 2026-04-21), Explore Investments LLC (6.6%, Schedule 13G/A, filed 2026-05-08) and Gates Frontier, LLC (5.6%, Schedule 13G, filed 2025-08-01).

Who are the largest shareholders of Lyell Immunopharma, Inc.?

By the share each holder's latest filing reports, the largest holders of Lyell Immunopharma, Inc. on this page are ARCH Venture Fund IX, L.P. (13.9%), Innovative Cellular Therapeutics Holdings Limited (12.3%) and Euler Fund, L.P. (6.71%).

When did ARCH Venture Fund IX, L.P. buy into Lyell Immunopharma, Inc.?

The filings give report dates, not purchase dates. The earliest filing from ARCH Venture Fund IX, L.P. on this page is the Schedule 13G/A, filed 2025-11-14, reporting 13%; its latest, Schedule 13G/A filed 2026-05-15, reports 13.9%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Lyell Immunopharma, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Lyell Immunopharma, Inc. is mentioned again
• Find former Lyell Immunopharma, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes